Grassley, Baucus, Colleagues Urge CMS to Continue Improving Medicare Drug Benefit Pharmacy Policies to Help Beneficiaries
WASHINGTON – Sen. Chuck Grassley, chairman of the Committee on Finance, Sen. Max Baucus, ranking Democrat, and 15 fellow senators are urging the Centers for Medicare and Medicaid Services (CMS) to continue improving Medicare prescription drug benefit policies to maintain maximum prescription drug access and streamline procedures for beneficiaries.
The senators corresponded with CMS on pharmacy issues earlier this year. On Friday, they sent a follow-up letter to clarify several points and urge CMS to consider their views. The text of the Oct. 27, 2006, letter follows.
The original letter and CMS’ response are attached.
October 27, 2006
The Honorable Leslie Norwalk, Esq.
Centers for Medicare & Medicaid Services
Department of Health and Human Services
200 Independence Avenue, SW
Washington, DC 20201
Dear Acting Administrator Norwalk:
We are writing to continue our dialogue initiated last July with then-Administrator McClellan on pharmacy-related issues under the Medicare prescription drug program. The September 27 response that we received from Dr. McClellan prior to his departure from the Centers for Medicare and Medicaid Services (CMS) suggests that some of our recommendations included in our July 17 letterto him may not have been clear. We also want to share additional thoughts on the Agency’s responses.
· Disclosure of Maximum Allowable Cost (MAC) List and Prices: In its response, the Agency stated that it “does not generally involve itself in dictating plan pharmacy contracting terms.” We are somewhat puzzled by that response because we did not suggest that CMS “dictate” contract terms. We simply recommended that CMS encourage plans to disclose MAC list and price information andany subsequent changes to ensure that pharmacists can fully assess the nature of the contract. Giventhe Agency’s response to our recommendation, we would like to learn more about other approachesit may take toward this end, especially because as stated in its response, CMS “strongly agrees thatreimbursement terms in network pharmacy contracts should be as specific and clear as possible.”
· Updating of Average Wholesale Prices (AWPs): Although prescription drug plan (PDP) sponsorsmay update AWP pricing on a “regular” basis, it is unclear whether these regular updates coincidewith their receipt of changes in AWP. We want to be clear in our view that there should be no lagbetween a PDP sponsor’s receipt of an AWP change and updates to its price list. The day on whicha PDP sponsor receives an AWP change is the day on which it should update its price list.
· Option for Electronic Funds Transfer (EFT): We appreciate that CMS requires PDP sponsors tooffer an EFT option. We also appreciate the effort of America’s Health Insurance Plans (AHIP) topromote EFT availability and utilization. In our view, though, promoting EFT availability andutilization is a responsibility that lies with the Agency, not with a trade association whosemembership does not encompass all PDP sponsors.
· Access to Extended Supplies of Part D Drugs at Retail Pharmacies: We understand that theMedicare Modernization Act of 2003 does not require that all pharmacies provide extended supplies.Our concern is that the Agency’s current policies may undermine the MMA requirements to ensure(1) beneficiaries’ access to their medicines through retail pharmacies and (2) level playing fieldbetween mail-order and retail pharmacies. With respect to the latter requirement, the statutory language on this matter at §1860D-4.(b)(1)(D) is not ambiguous. The MMA clearly states that sponsors “shall permit enrollees to receive benefits (which may include a 90-day supply of drugs orbiologicals) through a pharmacy (other than a mail order pharmacy), with any differentials in chargepaid by such enrollees.” Congressional intent behind this provision is obvious. The provision isintentionally designed as a requirement on plan sponsors to ensure that beneficiaries withprescriptions for longer term supplies can fill those prescriptions at either their local retail pharmacyor through mail order.
· Although we are pleased to know that CMS is monitoring complaints, we do not believe that thisapproach is sufficient to determine compliance and enforce contract requirements. In addition, thisapproach places the onus on the beneficiary to file a formal complaint, which is clearly not whatCongress intended. We believe that the Agency should be more proactive in ensuring PDP sponsors’compliance with the law and beneficiaries’ access to extended supplies in retail settings.
· Requirement Regarding Emergency Supplies Filled by Long-Term Care Pharmacies: We appreciate the Agency’s vigilance in ensuring that beneficiaries in long-term care facilities have access to medically necessary prescription medicines. We want to reiterate that beneficiaries in long-term care facilities often require an emergency fill. We expect the Agency to ensure that in thesecircumstances, prior authorization requirements do not hinder beneficiaries’ access to medications.
Thank you for your consideration of our comments.
Charles E. Grassley
Senators Salazar, Santorum, Rockefeller, Snowe, Kyl, Smith, Burr, Inouye, Conrad, DeWine, Lincoln, Burns, Cochran, Dole, Thomas
Next Article Previous Article
- Senate Passes Grassley, Brown, Scott, Wyden Legislation to Help Nonprofits
- ICYMI: Policymakers Must Work to Reduce Drug Prices
- Grassley, Daines, McSally Introduce Elder Justice Legislation to Boost Programs, Help Fight COVID in Nursing Homes
- Grassley Introduces the Updated Prescription Drug Pricing Reduction Act of 2020
- Grassley, Colleagues Introduce Updated Bipartisan Prescription Drug Pricing Bill